Alpha Tau Medical receives FDA clearance to expand its U.S. recurrent glioblastoma trial to 20 patients from 10, adding IDH-mutant grade 4 tumors and survival and quality-of-life assessments

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.